毛斐

毛斐

毛斐，女，博士，華東理工大學藥學院副教授。

基本介紹

  • 中文名：毛斐
  • 畢業院校：中山大學
  • 學位/學歷：博士
  • 職業：教師
  • 專業方向：多靶點抗AD創新藥物發現研究
  • 任職院校：華東理工大學
個人經歷,研究方向,學術成果,

個人經歷

2014年6月畢業於中山大學藥學院藥物化學專業，獲博士學位，後進入華東理工大學藥學院從事博士後研究，合作導師為李劍教授。2016年10月出站後留校工作，從事藥物化學教學和科研工作，2018年9月晉升副教授。

研究方向

  1. 多靶點抗AD創新藥物發現研究
  2. 抗耐藥菌創新藥物開發研究
  3. 抗腫瘤創新藥物開發研究
  4. 老藥二次開發研究

學術成果

作為項目負責人，先後主持國家自然科學基金青年基金1項、博士後科學基金（面上一等資助）1項、教育部高校基本科研業務費1項；2017年入選上海市“青年科技英才揚帆計畫”；2018年入選華東理工大學“青年英才培育計畫”A類。
迄今已在國內外重要刊物如J. Med. Chem.; Eur. J. Med. Chem.; ACS Chem. Neurosci.等上發表SCI論文40餘篇；申請發明專利14項（授權2項）；參編論著1部（藥物結構最佳化——設計策略和經驗規則）。
代表性論文(共同第一作者，*為通訊作者)
  1. Wenwen Liu, Huan Wang, Xiaokang Li, Yixiang Xu, Jian Zhang, Wei Wang, Qi Gong, Xiaoxia Qiu, Jin Zhu,Fei Mao*, Haiyan Zhang*, Jian Li*. Design, synthesis and evaluation of vilazodone-tacrine hybrids as multitarget-directed ligands against depression with cognitive impairment.Bioorg. Med. Chem.2018,
  2. Wei Ni, Huan Wang, Xiaokang Li, Xinyu Zheng, Manjiong Wang, Jian Zhang, Qi Gong, Dazheng Ling,Fei Mao*, Haiyan Zhang*, Jian Li*. Novel tadalafil derivatives ameliorates scopolamine-induced cognitive impairment in mice via inhibition of acetylcholinesterase (AChE) and phosphodiesterase 5 (PDE5).ACS Chem. Neurosci.2018,
  3. Baoli Li, Shuaishuai Ni,Fei Mao, Feifei Chen, Yifu Liu, Hanwen Wei, Wenhua Chen, Jin Zhu, Lefu Lan*, Jian Li*. Novel terminal bipheny-based diapophytoene desaturases (CrtN) inhibitors as anti-MRSA/VISR/LRSA agents with reduced hERG activity.J. Med. Chem.2018,
  4. Fei Mao, Huan Wang, Wei Ni, Xinyu Zheng, Manjiong Wang, Keting Bao, Dazheng Ling, Xiaokang Li, Yixiang Xu, Haiyan Zhang*, Jian Li*. Design, synthesis, and biological evaluation of orally available first-generation dual-target selective inhibitors of acetylcholinesterase (AChE) and phosphodiesterase 5 (PDE5) for the treatment of Alzheimer’s disease.ACS Chem. Neurosci.2018,
  5. Hanwen Wei,Fei Mao, Shuaishuai Ni, Feifei Chen, Baoli Li, Xiaoxia Qiu, Linghao Hu, Manjiong Wang, Xinyu Zheng, Jin Zhu, Lefu Lan*, Jian Li*. Discovery of novel piperonyl derivatives as diapophytoene desaturase inhibitors for the treatment of methicillin-, vancomycin- and linezolid-resistant Staphylococcus aureus infections.Eur. J. Med. Chem.2018
  6. Yi-xiang Xu, Huan Wang, Xiao-kang Li, Sheng-nan Dong, Wen-wen Liu, Qi Gong, Tian-duan-yi Wang, Yun Tang, Jin Zhu, Jian Li*, Hai-yan Zhang*,Fei Mao*. Discovery of novel propargylamine-modified 4-aminoalkyl imidazole substituted pyrimidinylthiourea derivatives as multifunctional agents for the treatment of Alzheimer's disease.Eur. J. Med. Chem.2018,
  7. Xiaokang Li, Huan Wang, Yixiang Xu, Wenwen Liu, Xiaoxia Qiu, Jin Zhu,Fei Mao*, Haiyan Zhang*, Jian Li*. Novel vilazodone-tacrine hybrids as potential multitarget-directed ligands for the treatment of Alzheimer’s disease accompanied with depression: design, synthesis and biological evaluation.ACS Chem. Neurosci.2017,
  8. Yanli Lu,Fei Mao, Xiaokang Li, Xinyu Zheng, Manjiong Wang, Qing Xu, Jin Zhu, and Jian Li*. Discovery of potent, selective stem cell factor receptor/platelet derived growth factor receptor alpha (c-KIT/PDGFRα) dual inhibitor for the treatment of imatinib-resistant gastrointestinal stromal tumors (GISTs).J. Med. Chem.2017,
  9. Xiaokang Li, Huan Wang, Zhengyu Lu, Xinyu Zheng, Wei Ni, Jin Zhu, Yan Fu, Fulin Lian, Naixia Zhang, Jian Li*, Haiyan Zhang*, andFei Mao*. Development of multifunctional pyrimidinylthiourea derivatives as potential anti-Alzheimer agents.J. Med. Chem.2016,
  10. Fei Mao, Qingya Kong, Wei Ni, Xiang Xu, Dazheng Ling, Zhengyu Lu, Jian Li*. Melting point distribution analysis of the global approved and discontinued drugs: a Research for improving the success chance of drug design and discovery.ChemistryOpen, 2016,
  11. Fei Mao, Wei Ni, Xiang Xu, Hui Wang, Jing Wang, Min Ji, Jian Li*. Chemical structure-related drug-like criteria of global approved drugs.Molecules2016,
  12. Dengwei Wu,Fei Mao,Yan Ye, Jian Li, Chuanlian Xu*, Xiaomin Luo, Jing Chen*, Xu Shen. Policresulen as a novel inhibitor of NS2B/NS3 protease efficiently suppressed the replication of DENV2 virus.Acta Pharmacol. Sin.2015,
  13. Fei Mao, Jianheng Li, Hui Wei, Ling Huang*, Xingshu Li*.Tacrine-propargylamine derivatives with improved acetylcholinesterase inhibitory activity and lower hepatotoxicity as a potential lead compound for the treatment of Alzheimer’s disease.J. Enzym. Inhib. Med. Chem.2015,
  14. Fei Mao, Jun Yan, Jian-heng Li, Yang sun, Xian Jia, Ling Huang*, Xing-shu Li*.New Multi-Target-Directed Small Molecules Against Alzheimer's Disease: a Combination of Resveratrol and Clioquinol.Org. Biomol. Chem.2014,
  15. Fei Mao, Jian-wen Chen*, Qi Zhou, Zong-hua Luo, Li Huang, Xing-shu Li*. Novel tacrine–ebselen hybrids with improved cholinesterase inhibitory, hydrogen peroxide and peroxynitrite scavenging activity.Bioorg. Med. Chem. Lett.2013,
  16. Fei Mao, Ling Huang, Zong-hua Luo, Anqiu Liu, Chuan-jun Lu, Zhi-yong Xie*, Xingshu Li*.O-Hydroxyl oro-amino benzylamine-tacrine hybrids: Multifunctional biometals chelators, antioxidants, and inhibitors of cholinesterase activity and amyloid-beta aggregation.Bioorgan. Med. Chem.2012,

相關詞條

熱門詞條

聯絡我們